Phase II study of dacarbazine given with modern prophylactic anti-emetics and growth factor support to patients with metastatic, resistant soft tissue, and bone sarcoma

Phase II study of dacarbazine given with modern prophylactic anti-emetics and growth factor support to patients with metastatic, resistant soft tissue, and bone sarcoma

Historically, administration of dacarbazine to sarcoma patients was limited by frequent treat-ment-related nausea/vomiting and neutropenia. These toxicities are now largely preventable with contemporary antiemetics and growth factor support. In this single-arm, phase II study, dacarbazine 850 mg/m 2...

Full description

Bibliographic Details
Main Authors: Brian A Van Tine, Mia C Weiss, Angela C Hirbe, Peter J Oppelt, Sarah Abaricia, Kathryn Trinkaus, Jingqin Luo, Shellie Berry, Tyler Ruff, Cheryl Callahan, Jacqui Toensikoetter, Jessica Ley, Marilyn J Siegel, Farrokh Dehdashti, Barry A Siegel, Douglas R Adkins
Format: Article
Language:English
Published: SAGE Publishing 2021-10-01
Series:Rare Tumors
Online Access:https://doi.org/10.1177/20363613211052498

Internet

https://doi.org/10.1177/20363613211052498

Similar Items